CP
Caligan Partners Portfolio holdings
AUM
$515M
This Quarter Return
+3.59%
1 Year Return
+70.09%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$428M
AUM Growth
+$428M
(+13%)
Cap. Flow
+$60.9M
Cap. Flow
% of AUM
14.24%
Top 10 Holdings %
Top 10 Hldgs %
96.18%
Holding
13
New
1
Increased
7
Reduced
1
Closed
–
Top Buys
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$23.7M |
| 2 |
Exelixis
EXEL
|
$9.55M |
| 3 |
Mineralys Therapeutics
MLYS
|
$8.73M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$7.91M |
| 5 |
IMAB
I-MAB
IMAB
|
$4.37M |
Top Sells
| 1 |
Y-mAbs Therapeutics
YMAB
|
$62.8K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Liquidia Corp
LQDA
$2.38B
| $124M | 29.05% |
10,360,945
| – | – |
|
|
ALIM
2
DELISTED
Alimera Sciences, Inc.
ALIM
| $93.6M | 21.87% |
16,835,154
| – | – |
|
3
Anika Therapeutics
ANIK
$135M
| $36.4M | 8.5% |
1,435,993
| – | – |
|
|
4
Exelixis
EXEL
$10.1B
| $34.3M | 8.01% |
1,525,730
+425,000
| +39% | +$9.55M |
|
|
5
BioCryst Pharmaceuticals
BCRX
$1.74B
| $28.4M | 6.64% |
4,598,737
+3,840,235
| +506% | +$23.7M |
|
|
VRNA
6
Verona Pharma
VRNA
$9.16B
| $26.7M | 6.23% |
1,843,756
+547,309
| +42% | +$7.91M |
|
7
Evolus
EOLS
$494M
| $23.5M | 5.5% |
2,167,790
+278,909
| +15% | +$3.03M |
|
8
Agios Pharmaceuticals
AGIO
$2.19B
| $22.2M | 5.19% |
514,711
+30,000
| +6% | +$1.29M |
|
9
Enanta Pharmaceuticals
ENTA
$180M
| $13.5M | 3.16% |
1,042,889
+184,819
| +22% | +$2.4M |
|
|
10
Mineralys Therapeutics
MLYS
$1.03B
| $8.73M | 2.04% |
+745,758
| New | +$8.73M |
|
|
11
Y-mAbs Therapeutics
YMAB
$388M
| $7.03M | 1.64% |
582,078
-5,198
| -0.9% | -$62.8K |
|
|
IMAB
12
I-MAB
IMAB
$340M
| $5.64M | 1.32% |
3,374,791
+2,618,253
| +346% | +$4.37M |
|
13
Outlook Therapeutics
OTLK
$37.8M
| $3.69M | 0.86% |
500,000
| – | – |
|